When was Atmo Biosciences founded?

Atmo Biosciences was founded in 2017 and raised its 1st funding round 2 years after it was founded.

Where is Atmo Biosciences located?

Atmo Biosciences is headquartered in Melbourne, Australia.

How many employees does Atmo Biosciences have?

As of Sep 30, 2026, the latest employee count at Atmo Biosciences is 35.

Is Atmo Biosciences a funded company?

Atmo Biosciences is a funded company, having raised a total of $7.01M across 4 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Mar 2019.

When was the latest funding round of Atmo Biosciences?

Atmo Biosciences' latest funding was a $***** Series B round on Sep 25, 2023, with participation from 1 investor.

Where does Atmo Biosciences rank among its competitors?

Atmo Biosciences ranks 37th amongst 469 active competitors, of which 56 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was FOXO Technologies, which secured $1.65M in Jun, 2025.

Who are the top competitors of Atmo Biosciences?

Atmo Biosciences' top competitors include Roche, Hologic and FOXO Technologies. Among them, FOXO Technologies secured the most recent funding round in June, 2025.

Atmo Biosciences - 2026 Company Profile, Funding & Competitors

Company Details

Atmo Biosciences is a spinoff of the RMIT University in Melbourne, Australia that is commercializing a swallowable gas sensor that can reliably profile and monitor intestinal gases such as hydrogen, carbon dioxide, oxygen, etc. in real time. The capsule seamlessly transmits the data to a smartphone. Atmo has partnered with Planet Innovation, a product development firm, to develop their technology as a diagnostic device for an array of gut disorders, from food nutrient malabsorption to colon cancer.

Website: www.atmobiosciences.com/
Email ID: *****@atmobiosciences.com

Key Metrics

Founded Year

2017

Location

Melbourne, Australia

Stage

Series B

Total Funding

$7.01M in 4 rounds

Latest Funding Round

Series B, Sep 25, 2023, $*****

Investors

Breakthrough Victoria & 3 more

Ranked

37^th among 469 active competitors

Employee Count

35 as on Sep 30, 2026

Similar Companies

Roche & 332 more

View Atmo Biosciences' full profile

Atmo Biosciences has raised a total funding of $7.01M over 4 rounds. Its first funding round was on Mar 2019. Its latest funding round was a Series B round on Sep 25, 2023 for $*****. 1 investor participated in its latest round. Atmo Biosciences has 4 institutional investors.

Here is the list of recent funding rounds of Atmo Biosciences:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 25, 2023	3368435	Series B	9989439	9923402	9054127	1351879
Mar 30, 2023	2168692	Series B	2902497	7387915	9257913	Otsuka
Jun 2020	8480919	Seed	4915471	2769589	4964835	1289773

Access funding benchmarks and valuations. Sign up today!

View details of Atmo Biosciences's funding rounds and investors

Atmo Biosciences' employee count trend

Atmo Biosciences has 35 employees as of Sep 26. Here is Atmo Biosciences's employee count trend over the years:

Employee count trend for Atmo Biosciences

Uncover Atmo Biosciences' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Atmo Biosciences include Roche, Hologic and FOXO Technologies. Here is the list of Top 10 competitors of Atmo Biosciences, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Roche 1896, Basel (Switzerland), Public	Developer of pharmaceuticals and diagnostics kits	-	Gilde Healthcare, SoftBank Group & 11 others	70/100
2nd	Hologic 1985, Marlborough (United States), Acquired	Manufacturer of medical diagnostic devices and systems for women health	-	Saints Capital, Triodos Investment Management ... & 3 others	67/100
3rd	FOXO Technologies 2020, Minneapolis (United States), Public	Provider of epigenetic diagnostic services alongside rural and behavioral hospitals	$40M	Bespoke Growth Partners, Inc., Centrecourt Asset Management ... Read more	60/100
4th	SonoSite 1986, Bothell (United States), Acquired	Point-of-care ultrasound solutions provider, empowering clinicians with advanced imaging	-	Europa	57/100
5th	NVision Imaging Technologies 2015, Ulm (Germany), Series A	Provider of medical imaging by quantum technologies	$35M	Playground Global, Kreissparkasse Esslingen Nurtingen ... & 8 others	56/100
6th	DiaSorin 1968, Saluggia (Italy), Public	Develops and commercializes reagent kits for in vitro diagnostics	-	Eiffel Investment Group, Public Health Emergency ... & 1 others	56/100
7th	Hangzhou Deshi Biotechnology 2016, Hangzhou (China), Public	Devices for HPV virus detection & RNA detection	$30.2M	Xiangjiang Liyuan Investment, Shenzhen Guozhong Venture Capital Management ... & 8 others	55/100
8th	numares 2004, Regensburg (Germany), Series B	Developer of diagnostic tests using metabolomics and nuclear magnetic resonance spectroscopy	$26.8M	Bayern Kapital, Kfw & 2 others	55/100
9th	Sysmex 1968, Kobe (Japan), Public	Developer of diagnostic instruments, reagents, and related software	-	-	55/100
10th	EKF 1990, Penarth (United Kingdom), Public	Develops point-of-care and laboratory blood analyzers	$179K	Octopus Investments, IBG Beteiligungsgesellschaft Sachsen-Anhalt ... & 2 others	54/100
37th	Atmo Biosciences 2017, Melbourne (Australia), Series B	Swallowable sensors for profiling intestinal gases	$7.01M	Alium Capital, Plug and Play APAC & 2 others	43/100